All In Biotech

Drug Trial Radar · NCT07499037

Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO

Low-dose Versus Standard-dose Anticoagulation With Argatroban and Enoxaparin During Extracorporeal Membrane Oxygenation Controlled by Anti-IIa and An-ti-Xa, Respectively

Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Sep 2029

Study completion Dec 2029

Sponsor

Lead sponsor
University Hospital OstravaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Motol
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.

Conditions

  • Pneumonia
  • Heart Failure

Interventions

  • Low anticoagulation dose of argatroban and enoxaparin during ECMODrug

    Study subjects in this group will receive low anticoagulation dose of argatroban and enoxaparin during ECMO

  • Standard anticoagulation dose of argatroban and enoxaparin during ECMODrug

    Study subjects in this group will receive standard anticoagulation dose of argatroban and enoxaparin during ECMO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of bleeding complicationsTime frame: During ECMO, up to 4 weeks
  2. Safety of thrombotic complicationsTime frame: During ECMO, up to 4 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospital Motol

    Prague, Czechia

  • University Hospital Ostrava

    Ostrava, Moravian-Silesian Region, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.